Skip Navigation LinksHome > November 2013 - Volume 23 - Issue 9 > The Effects of Metformin on Ovarian Cancer: A Systematic Rev...
International Journal of Gynecological Cancer:
doi: 10.1097/IGC.0b013e3182a80a21
Review Articles

The Effects of Metformin on Ovarian Cancer: A Systematic Review

Dilokthornsakul, Piyemeth PharmD*††; Chaiyakunapruk, Nathorn PharmD, PhD*†‡§; Termrungruanglert, Wichai MD; Pratoomsoot, Chayanin PhD; Saokeaw, Surasak PharmD*#; Sruamsiri, Rosarin BPharm, MBA*

Collapse Box

Abstract

Objective: The potential therapeutic effects of metformin on several cancers were reported. However, the evidence of the effects of metformin on ovarian cancer is still limited and inconclusive. This systematic review and meta-analysis study aims to summarize the existing evidence of the therapeutic effects of metformin on ovarian cancer.

Methods: We performed systematic searches using electronic databases including PubMed and EMBASE until December 2012. Key words included “metformin” AND (“ovarian cancer” OR “ovary tumor”). All human studies assessing the effects of metformin on ovarian cancer were eligible for inclusion. All articles were reviewed independently by 2 authors with a standardized approach for the purpose of study, study design, patient characteristics, exposure, and outcomes. The data were pooled using a random-effects model.

Results: Of 190 studies retrieved, only 3 observational studies and 1 report of 2 randomized controlled trials were included. Among those studies, 2 reported the effects of metformin on survival outcomes of ovarian cancer, whereas the other 2 reported the effects of metformin on ovarian cancer prevention. The findings of studies reporting the effects on survival outcomes indicated that metformin may prolong overall, disease-specific, and progression-free survival in ovarian cancer patients. The results of studies reporting the effects of metformin on ovarian cancer prevention were meta-analyzed. It indicated that metformin tended to decrease occurrence of ovarian cancer among diabetic patients with the pooled odds ratio of 0.57 (95% confidence interval, 0.16–1.99).

Conclusions: Our findings showed the potential therapeutic effects of metformin on survival outcomes of ovarian cancer and ovarian cancer prevention. However, most of the evidence was observational studies. There is a call for further well-conducted controlled clinical trials to confirm the effects of metformin on ovarian cancer survival and ovarian cancer prevention.

© 2013 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/IJGConline

For additional oncology content, visit LWW Oncology Journals on Facebook.